Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 4/20 | 0.38 |
| ▸ | NOS3 | P29474 | 2/20 | 0.33 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | NOS2 | P35228 | 2/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 4/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.31 |
| ▸ | ABL1 | P00519 | 3/20 | 0.31 |
| ▸ | EGFR | P00533 | 3/20 | 0.31 |
| ▸ | HCK | P08631 | 3/20 | 0.31 |
| ▸ | KDR | P35968 | 3/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.31 |
| ▸ | MTOR | P42345 | 3/20 | 0.31 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.31 |
| ▸ | PRKDC | P78527 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30475235 | 0.83 | PIK3CG (0.36) | PIK3CGNOS3NOS1NOS2 | |
| SCHEMBL22000962 | 0.83 | PIK3CG (0.36) | PIK3CGNOS3NOS1NOS2 | |
| SCHEMBL26424364 | 0.80 | PIK3CG (0.37) | PIK3CGNOS3NOS1NOS2 | |
| SCHEMBL24884329 | 0.78 | PIK3CG (0.37) | PIK3CGRET | |
| SCHEMBL24884299 | 0.78 | PIK3CG (0.37) | PIK3CGRET | |
| SCHEMBL2622408 | 0.76 | LMNA (0.40) | CYP1A2POLBCYP2C19SMN1; SMN2 | |
| SCHEMBL26151381 | 0.76 | ABL1 (0.33) | PIK3CGSRCPIK3CDABL1EGFR | |
| SCHEMBL12419716 | 0.74 | NOS3 (0.34) | NOS3NOS1NOS2CYP1A2POLB | |
| SCHEMBL19635048 | 0.73 | CYP1A2 (0.32) | CYP1A2POLBCYP2C19 | |
| SCHEMBL23403686 | 0.73 | KDM4E (0.32) | PIK3CGCYP1A2POLBCYP2C19SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376478-B1 | PYRIDYLOXYINDOLES INHIBITORS OF VEGF-R2 AND USE THEREOF FOR TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2017-04-19 | — | — | EP | claimed |
| EP-0900206-A1 | NEW DIAMINO PYRAZOLS, THEIR SYNTHESIS, KERATIN FIBRE DYEING COMPOSITIONS CONTAINING THEM, KERATIN FIBRE DYEING METHODS | L'OREAL (FR) | 1999-03-10 | — | — | EP | claimed |
| WO-1997042173-A1 | NEW DIAMINO PYRAZOLS, THEIR SYNTHESIS, KERATIN FIBRE DYEING COMPOSITIONS CONTAINING THEM, KERATIN FIBRE DYEING METHODS | L'OREAL (FR) | 1997-11-13 | — | — | WO | claimed |
| US-20250289792-A1 | 3-AMINO-4H-BENZO[E][1,2,4]THIADIAZINE 1,1-DIOXIDE DERIVATIVES AS INHIBITORS OF MRGX2 | SOLENT THERAPEUTICS LLC (US) | 2025-09-18 | — | — | US | disclosed |
| US-20250235543-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2025-07-24 | — | — | US | disclosed |
| CN-114072393-B | 3-Amino-4H-benzo [ E ] [1,2,4] thiadiazine 1, 1-dioxide derivatives as MRGX2 inhibitors | 索伦特治疗有限责任公司 | 2025-05-27 | — | — | CN | disclosed |
| US-12247015-B2 | 3-amino-4H-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of MRGX2 | SOLENT THERAPEUTICS, LLC (US) | 2025-03-11 | — | — | US | disclosed |
| EP-3604305-B1 | NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | WAKUNAGA PHARMA CO LTD (JP) | 2024-08-28 | — | — | EP | disclosed |
| CN-118451078-A | Modified proteins and protein degrading agents | 上海睿跃生物科技有限公司 | 2024-08-06 | — | — | CN | disclosed |
| US-11919858-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2024-03-05 | — | — | US | disclosed |
| US-11919858-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2024-03-05 | — | — | US | disclosed |
| US-8501756-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2013-08-06 | — | — | US | disclosed |
| US-8486954-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2013-07-16 | — | — | US | disclosed |
| US-8431584-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2013-04-30 | — | — | US | disclosed |
| US-20130012529-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2013-01-10 | — | — | US | disclosed |
| US-20130005753-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2013-01-03 | — | — | US | disclosed |
| US-20130005751-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2013-01-03 | — | — | US | disclosed |
| US-20120245187-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2012-09-27 | — | — | US | disclosed |
| WO-2010066684-A2 | Pyridyloxyindoles Inhibitors of VEGF-R2 and Use Thereof for Treatment of Disease | NOVARTIS AG (CH) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010066684-A2 | Pyridyloxyindoles Inhibitors of VEGF-R2 and Use Thereof for Treatment of Disease | NOVARTIS AG (CH) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005753-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | CDK2, PHKG1, PHKG2 | PIK3CG 84/4885NOS3 2646/4885NOS1 1963/4885 |
| US-12247015-B2 | 3-amino-4H-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of MRGX2 | TPX2, MRGPRX2, CBX2 | PIK3CG 3014/4885NOS3 2425/4885NOS1 2302/4885 |
| US-20250289792-A1 | 3-AMINO-4H-BENZO[E][1,2,4]THIADIAZINE 1,1-DIOXIDE DERIVATIVES AS INHIBITORS OF MRGX2 | TPX2, CBX2, RIOX2 | PIK3CG 3037/4885NOS3 2564/4885NOS1 2501/4885 |
| US-20120245187-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | CDK2, PHKG1, PHKG2 | PIK3CG 84/4885NOS3 2646/4885NOS1 1963/4885 |
| US-20130005751-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | CDK2, PHKG1, PHKG2 | PIK3CG 84/4885NOS3 2646/4885NOS1 1963/4885 |
| US-11919858-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | UBQLN1, PSMB1, UBQLN2 | PIK3CG 3082/4885NOS3 3615/4885NOS1 3603/4885 |
| US-20250235543-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, TP53BP1 | PIK3CG 4227/4885NOS3 4735/4885NOS1 4234/4885 |
| US-20130012529-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | CDK2, PHKG1, PHKG2 | PIK3CG 84/4885NOS3 2646/4885NOS1 1963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.